newsfilter
← Latest News
GlobeNewswire·

CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD

Single administration of CIDEBsiRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks Data from first-in-human trial were shared in oral presentation at AASLD